As the world leader in researching, developing and manufacturing influenza vaccine, sanofi pasteur responded to the threat of pandemic influenza by being the first company to utilize industrial-scale manufacturing capabilities for a pandemic H5N1 vaccine. Sanofi pasteur’s unique expertise is combined with a high-priority pandemic research program designed to bring constant innovation to its candidate vaccine before a pandemic is declared.

Sanofi pasteur’s pragmatic approach resulted in its current ability to manufacture a vaccine against H5N1 pandemic influenza. Once a pandemic is declared, the company commits to produce as many doses of sanofi pasteur’s most advanced vaccine candidate as quickly as possible.

June 16, 2008
Sanofi Pasteur to donate 60 million doses of H5N1 vaccine to WHO over 3 years for its influenza vaccine global stockpile
Download the press release "Sanofi Pasteur to donate 60 million doses of H5N1 vaccine to WHO..."